RxDoctor Payments Data

Lalita Bhamidipati, MD

Internal Medicine · Sarasota, FLNPI 1699765578

Payments from drug & device makers

$1,306in general payments, 2019–2025

Across 49 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$367
  • Amgen$205
  • Centinel Spine, LLC$155
  • AstraZeneca$141
  • Pfizer$134
  • Bayer$117
  • plus $187 from 4 others

What the payments were for

  • Food & beverage$1,306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC18$367
Amgen6$205
Centinel Spine, LLC1$155
AstraZeneca3$141
Pfizer7$134
Bayer5$117
Novo Nordisk5$98
AbbVie2$40
Exact Sciences1$31
Novartis1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,306 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$290,611
Medicare patients
757
Services billed
2,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$66,978
EliquisApixaban51$55,127
XareltoRivaroxaban19$30,038
JanuviaSitagliptin Phosphate14$20,288
MyrbetriqMirabegron24$14,761
TrulicityDulaglutide13$11,892
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,844
Levothyroxine Sodium790$7,614
Potassium Chloride123$6,871
Rosuvastatin Calcium465$6,736
SynthroidLevothyroxine Sodium104$5,959
Atorvastatin Calcium545$4,202
Metoprolol Succinate253$3,576
Losartan Potassium382$3,574
Estradiol81$3,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$98$66,97844 claims
PfizerEliquis$134$55,12751 claims
Lilly USA, LLCTrulicity$367$11,89213 claims
AbbVieSynthroid$40$5,959104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →